Betting Smarter, Not Harder: The Smart Investor's Secret to Massive Returns
Vijay Pande, the former CEO of a16z's roughly $4 billion biotech practice, has left the investment firm to start VZVC, a much smaller and AI-native venture capital firm. In an exclusive interview with me, Pande shared his insights on why biology is shifting from a discovery-driven science to an engineering discipline. According to him, this shift is driven by the increasing complexity of biological systems and the need for more data-driven approaches.
Clinical trials are still notoriously expensive, with many startups reporting costs that exceed $10 million per patient. This high cost barrier can make it challenging for new treatments to gain traction in the market. However, Pande believes that open, shared datasets - not walled-off ones - will be the key to unlocking innovation in medicine. By sharing data and collaborating across researchers, scientists can pool their expertise and accelerate discovery.
Pande's firm is taking a different approach than its predecessors. VZVC focuses on investing in AI-native startups, providing resources and expertise to help them develop more effective treatments. Pande's own experience in biotech has taught him that the biggest challenges lie not just in the biology itself but also in how we approach it. By betting smarter - not harder - on open datasets and collaborative research, he believes VZVC can make a real difference in the fight against disease.